Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soliris in generalized myasthenia gravis
NCT00727194Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2008
- Primary completion
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of eculizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Started Oct 2008; status: terminated.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT00727194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00727194.